Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: A meta-regression analysis

E. J. Mills, S. Kelly, M. Bradley, P. Mollon, C. Cooper, J. Nachega

Research output: Contribution to journalArticle

Abstract

Objective: Governments, clinicians and drug-licensing bodies have adopted changes in CD4 cell counts and HIV-1 RNA levels as evidence of effectiveness for new therapeutic interventions. We aimed to determine the strength of the association between the magnitude of the effect of changes in CD4 cell count and HIV-1 RNA and progression to AIDS or death in the highly active antiretroviral therapy (HAART) era. Methods: We identified all randomized clinical trials (RCTs) evaluating the effect of HAART on both clinical and surrogate endpoints (1994 to September 2006). We performed a meta-regression and weighted linear regression. We additionally estimated potential RCT sample sizes that would be required to assess the effectiveness of new interventions in terms of clinical endpoints. Results: We included data from 178 RCTs. We were unable to demonstrate a strong relationship at any time-point. Specifically, this was the case when CD4 T-cell change and clinical outcomes were examined at week 24 [coefficient -0.01, 95% confidence interval (CI) -0.03 to 0.001, P = 0.54], week 48 (coefficient -0.01, 95% CI -0.02 to 0.001, P = 0.83) and week 96 (coefficient 0.00, 95% CI -0.03 to 0.04, P = 0.76). This was also the case when viral load was examined as a surrogate marker. Given the small number of clinical events occurring in new interventional RCTs, any RCT aiming to evaluate clinical endpoints within these time-points would require an exceptionally large sample size. Conclusions: Our findings indicate that, within short-term clinical trial settings, it is not possible to estimate the proportion of treatment effect associated with surrogate endpoints.

Original languageEnglish (US)
Pages (from-to)849-857
Number of pages9
JournalHIV Medicine
Volume9
Issue number10
DOIs
StatePublished - Nov 2008

Fingerprint

CD4 Lymphocyte Count
Meta-Analysis
HIV-1
Acquired Immunodeficiency Syndrome
Randomized Controlled Trials
Regression Analysis
RNA
Biomarkers
Highly Active Antiretroviral Therapy
Confidence Intervals
Sample Size
Licensure
Viral Load
Linear Models
Clinical Trials
T-Lymphocytes
Therapeutics
Pharmaceutical Preparations

Keywords

  • HIV/AIDS
  • Meta-analysis
  • Surrogate markers

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy

Cite this

Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death : A meta-regression analysis. / Mills, E. J.; Kelly, S.; Bradley, M.; Mollon, P.; Cooper, C.; Nachega, J.

In: HIV Medicine, Vol. 9, No. 10, 11.2008, p. 849-857.

Research output: Contribution to journalArticle

Mills, E. J. ; Kelly, S. ; Bradley, M. ; Mollon, P. ; Cooper, C. ; Nachega, J. / Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death : A meta-regression analysis. In: HIV Medicine. 2008 ; Vol. 9, No. 10. pp. 849-857.
@article{67c9941a0688465ebd7937883dac5384,
title = "Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: A meta-regression analysis",
abstract = "Objective: Governments, clinicians and drug-licensing bodies have adopted changes in CD4 cell counts and HIV-1 RNA levels as evidence of effectiveness for new therapeutic interventions. We aimed to determine the strength of the association between the magnitude of the effect of changes in CD4 cell count and HIV-1 RNA and progression to AIDS or death in the highly active antiretroviral therapy (HAART) era. Methods: We identified all randomized clinical trials (RCTs) evaluating the effect of HAART on both clinical and surrogate endpoints (1994 to September 2006). We performed a meta-regression and weighted linear regression. We additionally estimated potential RCT sample sizes that would be required to assess the effectiveness of new interventions in terms of clinical endpoints. Results: We included data from 178 RCTs. We were unable to demonstrate a strong relationship at any time-point. Specifically, this was the case when CD4 T-cell change and clinical outcomes were examined at week 24 [coefficient -0.01, 95{\%} confidence interval (CI) -0.03 to 0.001, P = 0.54], week 48 (coefficient -0.01, 95{\%} CI -0.02 to 0.001, P = 0.83) and week 96 (coefficient 0.00, 95{\%} CI -0.03 to 0.04, P = 0.76). This was also the case when viral load was examined as a surrogate marker. Given the small number of clinical events occurring in new interventional RCTs, any RCT aiming to evaluate clinical endpoints within these time-points would require an exceptionally large sample size. Conclusions: Our findings indicate that, within short-term clinical trial settings, it is not possible to estimate the proportion of treatment effect associated with surrogate endpoints.",
keywords = "HIV/AIDS, Meta-analysis, Surrogate markers",
author = "Mills, {E. J.} and S. Kelly and M. Bradley and P. Mollon and C. Cooper and J. Nachega",
year = "2008",
month = "11",
doi = "10.1111/j.1468-1293.2008.00643.x",
language = "English (US)",
volume = "9",
pages = "849--857",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death

T2 - A meta-regression analysis

AU - Mills, E. J.

AU - Kelly, S.

AU - Bradley, M.

AU - Mollon, P.

AU - Cooper, C.

AU - Nachega, J.

PY - 2008/11

Y1 - 2008/11

N2 - Objective: Governments, clinicians and drug-licensing bodies have adopted changes in CD4 cell counts and HIV-1 RNA levels as evidence of effectiveness for new therapeutic interventions. We aimed to determine the strength of the association between the magnitude of the effect of changes in CD4 cell count and HIV-1 RNA and progression to AIDS or death in the highly active antiretroviral therapy (HAART) era. Methods: We identified all randomized clinical trials (RCTs) evaluating the effect of HAART on both clinical and surrogate endpoints (1994 to September 2006). We performed a meta-regression and weighted linear regression. We additionally estimated potential RCT sample sizes that would be required to assess the effectiveness of new interventions in terms of clinical endpoints. Results: We included data from 178 RCTs. We were unable to demonstrate a strong relationship at any time-point. Specifically, this was the case when CD4 T-cell change and clinical outcomes were examined at week 24 [coefficient -0.01, 95% confidence interval (CI) -0.03 to 0.001, P = 0.54], week 48 (coefficient -0.01, 95% CI -0.02 to 0.001, P = 0.83) and week 96 (coefficient 0.00, 95% CI -0.03 to 0.04, P = 0.76). This was also the case when viral load was examined as a surrogate marker. Given the small number of clinical events occurring in new interventional RCTs, any RCT aiming to evaluate clinical endpoints within these time-points would require an exceptionally large sample size. Conclusions: Our findings indicate that, within short-term clinical trial settings, it is not possible to estimate the proportion of treatment effect associated with surrogate endpoints.

AB - Objective: Governments, clinicians and drug-licensing bodies have adopted changes in CD4 cell counts and HIV-1 RNA levels as evidence of effectiveness for new therapeutic interventions. We aimed to determine the strength of the association between the magnitude of the effect of changes in CD4 cell count and HIV-1 RNA and progression to AIDS or death in the highly active antiretroviral therapy (HAART) era. Methods: We identified all randomized clinical trials (RCTs) evaluating the effect of HAART on both clinical and surrogate endpoints (1994 to September 2006). We performed a meta-regression and weighted linear regression. We additionally estimated potential RCT sample sizes that would be required to assess the effectiveness of new interventions in terms of clinical endpoints. Results: We included data from 178 RCTs. We were unable to demonstrate a strong relationship at any time-point. Specifically, this was the case when CD4 T-cell change and clinical outcomes were examined at week 24 [coefficient -0.01, 95% confidence interval (CI) -0.03 to 0.001, P = 0.54], week 48 (coefficient -0.01, 95% CI -0.02 to 0.001, P = 0.83) and week 96 (coefficient 0.00, 95% CI -0.03 to 0.04, P = 0.76). This was also the case when viral load was examined as a surrogate marker. Given the small number of clinical events occurring in new interventional RCTs, any RCT aiming to evaluate clinical endpoints within these time-points would require an exceptionally large sample size. Conclusions: Our findings indicate that, within short-term clinical trial settings, it is not possible to estimate the proportion of treatment effect associated with surrogate endpoints.

KW - HIV/AIDS

KW - Meta-analysis

KW - Surrogate markers

UR - http://www.scopus.com/inward/record.url?scp=55649096214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649096214&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2008.00643.x

DO - 10.1111/j.1468-1293.2008.00643.x

M3 - Article

C2 - 18795965

AN - SCOPUS:55649096214

VL - 9

SP - 849

EP - 857

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 10

ER -